Public dataset

Recorded source agreement and disagreement

Show whether sources print one normalized reading, have incompatible units, lack structured comparison context, or contain a context-matched numeric difference.

What this does not mean: agree can mean only that sources print the same normalized reading; it is not clinical-context equivalence, independent replication, or proof. differ requires matching structured context and disjoint comparable values. not_comparable and insufficient_context are not disagreement.

Public rows: 1,681
Generated: 2026-09-12
Schema version: source-consensus/2

Coverage

What this run contains

Compared medicine fields: 1,681
Agree: 1,282
Differ: 0
Not comparable: 12
Insufficient context: 387
Fields represented: 5; bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution

Method

How the rows were made

Deterministic rules normalize recorded pharmacokinetic readings and compare only like-for-like values.
One normalized printed reading may be agree even when clinical context was not extracted; this reports printed-reading agreement only.
Distinct readings may differ only when their units and denominators are comparable and one matching, non-placeholder population/formulation context was structurally extracted. Otherwise they are insufficient_context.
not_comparable preserves incompatible units or denominators instead of guessing. insufficient_context preserves missing or non-matching structured context instead of manufacturing agreement or disagreement.
The agreement rate describes the distribution of recorded source readings; it is not a probability that a value is true.
Every distinct printed reading retains its unit, population context, source count, and complete source records. The API paginates field rows, never child readings or sources.
documentsExamined is every matching single-substance archive document inspected for that medicine. The generator has no document, reading, or source ceiling, so there is no hidden available-versus-retained remainder.

Limits

Read these before using a row

Current label parsing does not structurally extract population or formulation context. Distinct otherwise-comparable readings are therefore insufficient_context, never differ; agree may mean printed-reading agreement only. Source records are complete but are not independent-experiment counts.
The current deterministic parser does not structurally extract population or formulation context from these sentences. It records that context as unknown and cannot publish distinct same-unit readings as differ.
Neither reading is marked wrong. Population, formulation, route, and other unextracted context may explain the printed difference.
Only the recorded fields and source documents in this snapshot are compared.
A source count is the number of retained source records in the row, not a count of independent experiments.

Provenance

Source examples

abacavir · bioavailability · agree

15 documents examined; 83% (Unknown: population and formulation context were not structurally extracted from this source sentence.)

FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b

The geometric mean absolute bioavailability of the tablet was 83%.

alemtuzumab · volumeOfDistribution · not_comparable

2 documents examined; 0.18 L/kg (Unknown: population and formulation context were not structurally extracted from this source sentence.); 14.1 L (Unknown: population and formulation context were not structurally extracted from this source sentence.)

FDA_LABEL:4f5f7255-7abc-4328-bd1a-ceaf139ef3e0

Distribution After the last 30 mg dose, the mean volume of distribution at steady-state was 0.18 L/kg (range 0.1 to 0.4 L/kg).

abiraterone · halfLife · insufficient_context

31 documents examined; 12 ± 5 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.); 18 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.)

FDA_LABEL:c9eb9b46-f847-40a8-802c-a51b40406d5a

Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.

Artifact used for this view: data/source-consensus.ndjson. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.

Schema

Fields in the public projection

Field	Type	Meaning
medicineSlug	string	Stable RNAWiki medicine route key.
field	string	Recorded pharmacokinetic field being compared.
comparisonState	string	agree (printed-reading agreement), differ (context-matched comparable disjoint values), not_comparable (unit/denominator mismatch), or insufficient_context. Every state remains declared even when its current count is zero.
comparisonReasons	string[]	Deterministic codes explaining the state.
documentsExamined	number	Recorded source documents considered for the field.
sourceCount	number	Recorded source readings represented.
agreementRate	number	Share represented by the leading normalized printed-reading group; not a confidence score or clinical agreement probability.
readings	consensus-reading[]	Complete, untruncated reading groups. Each keeps the printed display, numeric value when parsed, unit, population context, source count, and every source identity, version/effective date or explicit absence, retrieval date, locator, safe link, and excerpt.

Reader

Search and filter the rows

Showing 51–60 of 1,681 matching rows. Filters and search terms remain attached when you move between pages or open the API view.

Projected row 51
Medicine slug
almotriptan
Compared field
bioavailability
Comparison state
agree
Reason codes
- COMPATIBLE_VALUES_OVERLAP
Documents examined
2
Source count
2
Agreement rate
1
Recorded readings
1. 70%
  Numeric value
  70
  Unit
  %
  Source records
  2
  Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
  Show all 2 source records
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:35617039-9f33-401b-bac3-8f85c65fa2c7 (opens source in a new tab)
  Almotriptan label
  Version not recorded · Effective date not recorded
  12.3 Pharmacokinetics Absorption The absolute bioavailability of almotriptan is about 70%, with peak plasma levels occurring 1 to 3 hours after administration; food does not affect pharmacokinetics.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:6fa380c4-c885-4743-85bf-88819ae68645 (opens source in a new tab)
  Almotriptan label
  Version not recorded · Effective date not recorded
  12.3 Pharmacokinetics Absorption The absolute bioavailability of almotriptan is about 70%, with peak plasma levels occurring 1 to 3 hours after administration; food does not affect pharmacokinetics.
Projected row 52
Medicine slug
almotriptan
Compared field
halfLife
Comparison state
agree
Reason codes
- COMPATIBLE_VALUES_OVERLAP
Documents examined
2
Source count
2
Agreement rate
1
Recorded readings
1. 3 to 4 hours
  Numeric value
  3
  Unit
  hours
  Source records
  2
  Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
  Show all 2 source records
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:35617039-9f33-401b-bac3-8f85c65fa2c7 (opens source in a new tab)
  Almotriptan label
  Version not recorded · Effective date not recorded
  Excretion Almotriptan has a mean half-life of 3 to 4 hours.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:6fa380c4-c885-4743-85bf-88819ae68645 (opens source in a new tab)
  Almotriptan label
  Version not recorded · Effective date not recorded
  Excretion Almotriptan has a mean half-life of 3 to 4 hours.
Projected row 53
Medicine slug
almotriptan
Compared field
volumeOfDistribution
Comparison state
agree
Reason codes
- COMPATIBLE_VALUES_OVERLAP
Documents examined
2
Source count
2
Agreement rate
1
Recorded readings
1. 180 to 200 liters
  Numeric value
  180
  Unit
  L
  Source records
  2
  Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
  Show all 2 source records
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:35617039-9f33-401b-bac3-8f85c65fa2c7 (opens source in a new tab)
  Almotriptan label
  Version not recorded · Effective date not recorded
  Distribution Almotriptan is minimally protein bound (approximately 35%) and the mean apparent volume of distribution is approximately 180 to 200 liters.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:6fa380c4-c885-4743-85bf-88819ae68645 (opens source in a new tab)
  Almotriptan label
  Version not recorded · Effective date not recorded
  Distribution Almotriptan is minimally protein bound (approximately 35%) and the mean apparent volume of distribution is approximately 180 to 200 liters.
Projected row 54
Medicine slug
alogliptin
Compared field
bioavailability
Comparison state
agree
Reason codes
- COMPATIBLE_VALUES_OVERLAP
Documents examined
6
Source count
6
Agreement rate
1
Recorded readings
1. 100%
  Numeric value
  100
  Unit
  %
  Source records
  6
  Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
  Show all 6 source records
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:f2ad6d21-8060-42c7-8b3f-ad80085dc022 (opens source in a new tab)
  Alogliptin label
  Version not recorded · Effective date not recorded
  The absolute bioavailability of alogliptin tablets is approximately 100%.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:b25f155a-1259-47c2-aa3b-7c1356e4c7f6 (opens source in a new tab)
  Alogliptin label
  Version not recorded · Effective date not recorded
  The absolute bioavailability of alogliptin tablets is approximately 100%.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:38d30e4f-4212-4f7a-96b5-74b277b56cba (opens source in a new tab)
  Alogliptin label
  Version not recorded · Effective date not recorded
  Absorption The absolute bioavailability of alogliptin tablets is approximately 100%.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:a05d6d17-79f9-4788-a4d5-467bca1a2d91 (opens source in a new tab)
  Alogliptin label
  Version not recorded · Effective date not recorded
  Absorption The absolute bioavailability of alogliptin tablets is approximately 100%.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:4b007011-547a-498e-b8f6-34ea4ea00eb4 (opens source in a new tab)
  Alogliptin label
  Version not recorded · Effective date not recorded
  Absorption The absolute bioavailability of alogliptin tablets is approximately 100%.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:a3768c7e-aa4c-44d3-bc53-43bb7346c0b0 (opens source in a new tab)
  Alogliptin label
  Version not recorded · Effective date not recorded
  The absolute bioavailability of NESINA is approximately 100%.
Projected row 55
Medicine slug
alogliptin
Compared field
halfLife
Comparison state
agree
Reason codes
- COMPATIBLE_VALUES_OVERLAP
Documents examined
6
Source count
6
Agreement rate
1
Recorded readings
1. 21 hours
  Numeric value
  21
  Unit
  hours
  Source records
  6
  Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
  Show all 6 source records
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:f2ad6d21-8060-42c7-8b3f-ad80085dc022 (opens source in a new tab)
  Alogliptin label
  Version not recorded · Effective date not recorded
  Elimination Alogliptin tablets was eliminated with a mean terminal half-life (t 1/2 ) of approximately 21 hours.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:b25f155a-1259-47c2-aa3b-7c1356e4c7f6 (opens source in a new tab)
  Alogliptin label
  Version not recorded · Effective date not recorded
  Elimination Alogliptin tablets was eliminated with a mean terminal half-life (t 1/2 ) of approximately 21 hours.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:38d30e4f-4212-4f7a-96b5-74b277b56cba (opens source in a new tab)
  Alogliptin label
  Version not recorded · Effective date not recorded
  At the maximum recommended clinical dose of 25 mg, alogliptin tablets were eliminated with a mean terminal half-life (T 1/2 ) of approximately 21 hours.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:a05d6d17-79f9-4788-a4d5-467bca1a2d91 (opens source in a new tab)
  Alogliptin label
  Version not recorded · Effective date not recorded
  At the maximum recommended clinical dose of 25 mg, alogliptin tablets were eliminated with a mean terminal half-life (T 1/2 ) of approximately 21 hours.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:4b007011-547a-498e-b8f6-34ea4ea00eb4 (opens source in a new tab)
  Alogliptin label
  Version not recorded · Effective date not recorded
  At the maximum recommended clinical dose of 25 mg, alogliptin tablets were eliminated with a mean terminal half-life (T 1/2 ) of approximately 21 hours.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:a3768c7e-aa4c-44d3-bc53-43bb7346c0b0 (opens source in a new tab)
  Alogliptin label
  Version not recorded · Effective date not recorded
  Elimination NESINA was eliminated with a mean terminal half-life (t 1/2 ) of approximately 21 hours.
Projected row 56
Medicine slug
alogliptin
Compared field
volumeOfDistribution
Comparison state
agree
Reason codes
- COMPATIBLE_VALUES_OVERLAP
Documents examined
6
Source count
6
Agreement rate
1
Recorded readings
1. 417 L
  Numeric value
  417
  Unit
  L
  Source records
  6
  Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
  Show all 6 source records
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:f2ad6d21-8060-42c7-8b3f-ad80085dc022 (opens source in a new tab)
  Alogliptin label
  Version not recorded · Effective date not recorded
  Distribution Following a single, 12.5 mg intravenous infusion of alogliptin to healthy subjects, the volume of distribution during the terminal phase was 417 L, indicating that the drug is well distributed into tissues.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:b25f155a-1259-47c2-aa3b-7c1356e4c7f6 (opens source in a new tab)
  Alogliptin label
  Version not recorded · Effective date not recorded
  Distribution Following a single, 12.5 mg intravenous infusion of alogliptin to healthy subjects, the volume of distribution during the terminal phase was 417 L, indicating that the drug is well distributed into tissues.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:38d30e4f-4212-4f7a-96b5-74b277b56cba (opens source in a new tab)
  Alogliptin label
  Version not recorded · Effective date not recorded
  Distribution Following a single, 12.5 mg intravenous infusion of alogliptin to healthy subjects, the volume of distribution during the terminal phase was 417 L, indicating that the drug is well distributed into tissues.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:a05d6d17-79f9-4788-a4d5-467bca1a2d91 (opens source in a new tab)
  Alogliptin label
  Version not recorded · Effective date not recorded
  Distribution Following a single, 12.5 mg intravenous infusion of alogliptin to healthy subjects, the volume of distribution during the terminal phase was 417 L, indicating that the drug is well distributed into tissues.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:4b007011-547a-498e-b8f6-34ea4ea00eb4 (opens source in a new tab)
  Alogliptin label
  Version not recorded · Effective date not recorded
  Distribution Following a single, 12.5 mg intravenous infusion of alogliptin to healthy subjects, the volume of distribution during the terminal phase was 417 L, indicating that the drug is well distributed into tissues.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:a3768c7e-aa4c-44d3-bc53-43bb7346c0b0 (opens source in a new tab)
  Alogliptin label
  Version not recorded · Effective date not recorded
  Distribution Following a single, 12.5 mg intravenous infusion of alogliptin to healthy subjects, the volume of distribution during the terminal phase was 417 L, indicating that the drug is well distributed into tissues.
Projected row 57
Medicine slug
alosetron
Compared field
bioavailability
Comparison state
agree
Reason codes
- COMPATIBLE_VALUES_OVERLAP
Documents examined
9
Source count
9
Agreement rate
1
Recorded readings
1. 50%
  Numeric value
  50
  Unit
  %
  Source records
  9
  Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
  Show all 9 source records
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:3ac203a2-4c55-deac-e063-6394a90aa165 (opens source in a new tab)
  Alosetron label
  Version not recorded · Effective date not recorded
  Absorption: Alosetron was rapidly absorbed after oral administration with a mean absolute bioavailability of approximately 50% to 60% (approximate range, 30% to > 90%).
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:35cbb9d5-639b-207a-e054-00144ff88e88 (opens source in a new tab)
  Alosetron label
  Version not recorded · Effective date not recorded
  Absorption: Alosetron was rapidly absorbed after oral administration with a mean absolute bioavailability of approximately 50% to 60% (approximate range, 30% to >90%).
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:c216e967-436f-475a-8e6a-2ad11adc63af (opens source in a new tab)
  Alosetron label
  Version not recorded · Effective date not recorded
  Absorption: Alosetron was rapidly absorbed after oral administration with a mean absolute bioavailability of approximately 50% to 60% (approximate range, 30% to >90%).
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:da94d161-0bf0-48fe-90f4-8e38ae18e1ca (opens source in a new tab)
  Alosetron label
  Version not recorded · Effective date not recorded
  Absorption: Alosetron was rapidly absorbed after oral administration with a mean absolute bioavailability of approximately 50% to 60% (approximate range, 30% to >90%).
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:d62b2c5a-1693-4e67-96d5-197e1fdc8694 (opens source in a new tab)
  Alosetron label
  Version not recorded · Effective date not recorded
  Absorption: Alosetron was rapidly absorbed after oral administration with a mean absolute bioavailability of approximately 50% to 60% (approximate range, 30% to >90%).
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:38f5341f-5ae3-46bf-8bfc-30dff2068477 (opens source in a new tab)
  Alosetron label
  Version not recorded · Effective date not recorded
  Absorption: Alosetron was rapidly absorbed after oral administration with a mean absolute bioavailability of approximately 50% to 60% (approximate range, 30% to >90%).
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:ba94ab71-11d7-4ce1-9b21-0b8c6a39e993 (opens source in a new tab)
  Alosetron label
  Version not recorded · Effective date not recorded
  Absorption: Alosetron was rapidly absorbed after oral administration with a mean absolute bioavailability of approximately 50% to 60% (approximate range, 30% to >90%).
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:2846a244-7540-442b-81bc-638e641497ce (opens source in a new tab)
  Alosetron label
  Version not recorded · Effective date not recorded
  Absorption: Alosetron was rapidly absorbed after oral administration with a mean absolute bioavailability of approximately 50% to 60% (approximate range, 30% to >90%).
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:2927e7d0-b1b8-4944-a7e8-97b60eb9bb71 (opens source in a new tab)
  Alosetron label
  Version not recorded · Effective date not recorded
  Absorption: Alosetron was rapidly absorbed after oral administration with a mean absolute bioavailability of approximately 50% to 60% (approximate range, 30% to > 90%).
Projected row 58
Medicine slug
alosetron
Compared field
halfLife
Comparison state
agree
Reason codes
- COMPATIBLE_VALUES_OVERLAP
Documents examined
9
Source count
9
Agreement rate
1
Recorded readings
1. 1.5 hours
  Numeric value
  1.5
  Unit
  hours
  Source records
  9
  Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
  Show all 9 source records
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:3ac203a2-4c55-deac-e063-6394a90aa165 (opens source in a new tab)
  Alosetron label
  Version not recorded · Effective date not recorded
  The terminal elimination half-life of alosetron is approximately 1.5 hours (plasma clearance is approximately 600 mL/min).
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:35cbb9d5-639b-207a-e054-00144ff88e88 (opens source in a new tab)
  Alosetron label
  Version not recorded · Effective date not recorded
  The terminal elimination half-life of alosetron is approximately 1.5 hours (plasma clearance is approximately 600 mL/min).
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:c216e967-436f-475a-8e6a-2ad11adc63af (opens source in a new tab)
  Alosetron label
  Version not recorded · Effective date not recorded
  The terminal elimination half-life of alosetron is approximately 1.5 hours (plasma clearance is approximately 600 mL/min).
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:da94d161-0bf0-48fe-90f4-8e38ae18e1ca (opens source in a new tab)
  Alosetron label
  Version not recorded · Effective date not recorded
  The terminal elimination half-life of alosetron is approximately 1.5 hours (plasma clearance is approximately 600 mL/min).
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:d62b2c5a-1693-4e67-96d5-197e1fdc8694 (opens source in a new tab)
  Alosetron label
  Version not recorded · Effective date not recorded
  The terminal elimination half-life of alosetron is approximately 1.5 hours (plasma clearance is approximately 600 mL/min).
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:38f5341f-5ae3-46bf-8bfc-30dff2068477 (opens source in a new tab)
  Alosetron label
  Version not recorded · Effective date not recorded
  The terminal elimination half-life of alosetron is approximately 1.5 hours (plasma clearance is approximately 600 mL/min).
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:ba94ab71-11d7-4ce1-9b21-0b8c6a39e993 (opens source in a new tab)
  Alosetron label
  Version not recorded · Effective date not recorded
  The terminal elimination half-life of alosetron is approximately 1.5 hours (plasma clearance is approximately 600 mL/min).
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:2846a244-7540-442b-81bc-638e641497ce (opens source in a new tab)
  Alosetron label
  Version not recorded · Effective date not recorded
  The terminal elimination half-life of alosetron is approximately 1.5 hours (plasma clearance is approximately 600 mL/min).
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:2927e7d0-b1b8-4944-a7e8-97b60eb9bb71 (opens source in a new tab)
  Alosetron label
  Version not recorded · Effective date not recorded
  The terminal elimination half-life of alosetron is approximately 1.5 hours (plasma clearance is approximately 600 mL/min).
Projected row 59
Medicine slug
alosetron
Compared field
proteinBinding
Comparison state
agree
Reason codes
- COMPATIBLE_VALUES_OVERLAP
Documents examined
9
Source count
9
Agreement rate
1
Recorded readings
1. 82%
  Numeric value
  82
  Unit
  %
  Source records
  9
  Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
  Show all 9 source records
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:3ac203a2-4c55-deac-e063-6394a90aa165 (opens source in a new tab)
  Alosetron label
  Version not recorded · Effective date not recorded
  Plasma protein binding is 82% over a concentration range of 20 ng/mL to 4,000 ng/mL.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:35cbb9d5-639b-207a-e054-00144ff88e88 (opens source in a new tab)
  Alosetron label
  Version not recorded · Effective date not recorded
  Plasma protein binding is 82% over a concentration range of 20 to 4,000 ng/mL.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:c216e967-436f-475a-8e6a-2ad11adc63af (opens source in a new tab)
  Alosetron label
  Version not recorded · Effective date not recorded
  Plasma protein binding is 82% over a concentration range of 20 to 4,000 ng/mL.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:da94d161-0bf0-48fe-90f4-8e38ae18e1ca (opens source in a new tab)
  Alosetron label
  Version not recorded · Effective date not recorded
  Plasma protein binding is 82% over a concentration range of 20 to 4,000 ng/mL.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:d62b2c5a-1693-4e67-96d5-197e1fdc8694 (opens source in a new tab)
  Alosetron label
  Version not recorded · Effective date not recorded
  Plasma protein binding is 82% over a concentration range of 20 to 4,000 ng/mL.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:38f5341f-5ae3-46bf-8bfc-30dff2068477 (opens source in a new tab)
  Alosetron label
  Version not recorded · Effective date not recorded
  Plasma protein binding is 82% over a concentration range of 20 to 4,000 ng/mL.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:ba94ab71-11d7-4ce1-9b21-0b8c6a39e993 (opens source in a new tab)
  Alosetron label
  Version not recorded · Effective date not recorded
  Plasma protein binding is 82% over a concentration range of 20 to 4,000 ng/mL.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:2846a244-7540-442b-81bc-638e641497ce (opens source in a new tab)
  Alosetron label
  Version not recorded · Effective date not recorded
  Plasma protein binding is 82% over a concentration range of 20 to 4,000 ng/mL.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:2927e7d0-b1b8-4944-a7e8-97b60eb9bb71 (opens source in a new tab)
  Alosetron label
  Version not recorded · Effective date not recorded
  Plasma protein binding is 82% over a concentration range of 20 ng/mL to 4,000 ng/mL.
Projected row 60
Medicine slug
alosetron
Compared field
tMax
Comparison state
agree
Reason codes
- COMPATIBLE_VALUES_OVERLAP
Documents examined
9
Source count
9
Agreement rate
1
Recorded readings
1. 1 hour
  Numeric value
  1
  Unit
  hours
  Source records
  9
  Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
  Show all 9 source records
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:3ac203a2-4c55-deac-e063-6394a90aa165 (opens source in a new tab)
  Alosetron label
  Version not recorded · Effective date not recorded
  Following oral administration of a 1 mg alosetron dose to young men, a peak plasma concentration of approximately 5 ng/mL occurred at 1 hour.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:35cbb9d5-639b-207a-e054-00144ff88e88 (opens source in a new tab)
  Alosetron label
  Version not recorded · Effective date not recorded
  Following oral administration of a 1 mg alosetron dose to young men, a peak plasma concentration of approximately 5 ng/mL occurred at 1 hour.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:c216e967-436f-475a-8e6a-2ad11adc63af (opens source in a new tab)
  Alosetron label
  Version not recorded · Effective date not recorded
  Following oral administration of a 1 mg alosetron dose to young men, a peak plasma concentration of approximately 5 ng/mL occurred at 1 hour.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:da94d161-0bf0-48fe-90f4-8e38ae18e1ca (opens source in a new tab)
  Alosetron label
  Version not recorded · Effective date not recorded
  Following oral administration of a 1 mg alosetron dose to young men, a peak plasma concentration of approximately 5 ng/mL occurred at 1 hour.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:d62b2c5a-1693-4e67-96d5-197e1fdc8694 (opens source in a new tab)
  Alosetron label
  Version not recorded · Effective date not recorded
  Following oral administration of a 1 mg alosetron dose to young men, a peak plasma concentration of approximately 5 ng/mL occurred at 1 hour.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:38f5341f-5ae3-46bf-8bfc-30dff2068477 (opens source in a new tab)
  Alosetron label
  Version not recorded · Effective date not recorded
  Following oral administration of a 1 mg alosetron dose to young men, a peak plasma concentration of approximately 5 ng/mL occurred at 1 hour.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:ba94ab71-11d7-4ce1-9b21-0b8c6a39e993 (opens source in a new tab)
  Alosetron label
  Version not recorded · Effective date not recorded
  Following oral administration of a 1 mg alosetron dose to young men, a peak plasma concentration of approximately 5 ng/mL occurred at 1 hour.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:2846a244-7540-442b-81bc-638e641497ce (opens source in a new tab)
  Alosetron label
  Version not recorded · Effective date not recorded
  Following oral administration of a 1 mg alosetron dose to young men, a peak plasma concentration of approximately 5 ng/mL occurred at 1 hour.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:2927e7d0-b1b8-4944-a7e8-97b60eb9bb71 (opens source in a new tab)
  Alosetron label
  Version not recorded · Effective date not recorded
  Following oral administration of a 1 mg alosetron dose to young men, a peak plasma concentration of approximately 5 ng/mL occurred at 1 hour.

Access

Query or download the projection

View this filtered page as JSON Download up to 200 filtered CSV rows

GET /api/datasets/source-consensus?limit=10&offset=50

Allowed query parameters

q: Case-insensitive text search over the public fields named for this dataset.
state: Exact comparability state.Values: agree, differ, not_comparable, insufficient_context
field: Exact recorded field key.Values: bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
limit / offset: Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.

Reuse and corrections

Keep the boundary attached

CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.

Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.

Read the correction policy